HENDERSON, Nev., Sept. 13,
2023 /PRNewswire/ -- VolitionRx Limited (NYSE
AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company,
is hosting a Key Opinion Leader ("KOL") roundtable discussion in
Athens this weekend, bringing
together world-renowned experts in sepsis.
Chaired by Professor Djillali
Annane, Professor of Medicine at University Paris
Saclay-UVSQ , and one of the world's leading specialists in sepsis,
the session will include the challenges of sepsis, the connection
between Neutrophil Extracellular Traps ("NETs") and sepsis and how
Volition's Nu.Q® NETs technology could potentially be used
effectively in clinical practice.
Volition's event is being hosted by Professor Evangelos J. Giamarellos-Bourboulis, Professor
of Internal Medicine at The National and Kapodistrian University of
Athens in Greece and Chairman of the European Sepsis
Alliance.
Professor Djillali Annane said:
"We are delighted to bring together some of the world's most
distinguished experts in the field of sepsis, spanning a wide range
of specialisms including intensive care medicine, paediatric
sepsis, immunology, ctDNA, haematology, and critical care
medicine.
"Together, we will discuss the challenges we face in detecting
and treating sepsis, and the role of NETs. We will share research
around potential treatments, examine different approaches to
personalizing care, and consider how best to introduce pioneering
diagnostic tools, like Volition's Nu.Q® NETs test, into clinical
practice."
Dr. Andrew Retter, Medical
Consultant at Volition and a leading UK-based Intensive Care
Consultant added: "Nu.Q® NETs, Volition's nucleosome quantification
technology, is a simple, low cost and routine blood test which can
detect clinically elevated levels of NETs by identifying the unique
biomarker H3.1. Composed of decondensed chromatin, NETs play an
important role in our immune system with a unique ability to
counter infections by trapping and killing bacterial and viral
particles. However, abnormal levels have been linked to a range of
life-threatening conditions including severe sepsis, where they can
provide valuable prognostic information.
"Volition is committed to collaborating closely with KOLs and
centers of excellence worldwide, to ensure that the Nu.Q® NETs test
can be introduced effectively into clinical settings, to advance
patient care and improve outcomes. We look forward to sharing the
outputs from this invaluable KOL roundtable."
Volition's Nu.Q® NETs test is CE-marked, enabling clinical use
across Europe. Volition continues
to liaise with the United States Food and Drug Administration
regarding its U.S. clinical and regulatory program.
Sepsis is the number one cause of death in hospitals worldwide
and accounts for at least 11 million deaths per year. Volition's
event takes place during Sepsis Awareness Month and coincides with
World Sepsis Day, a global initiative to raise awareness around the
disease.
Notes
- Sepsis arises when the body's response to an infection injures
its own tissues and organs. It may lead to shock, multi-organ
failure, and death – especially if not recognized early and treated
promptly. (Global Sepsis Alliance - World Sepsis Day website)
- A recent study estimated that in 2017 there were 48.9 million
cases and 11 million sepsis-related deaths worldwide, which
accounted for almost 20% of all global deaths. (World Health
Organisation).
- In 2017, almost half of all global sepsis cases occurred among
children, with an estimated 20 million cases and 2.9 million global
deaths in children under 5 years of age. (World Health
Organisation).
About Volition
Volition is a multi-national epigenetics company powered by
Nu.Q®, its proprietary nucleosome quantification platform. Through
its subsidiaries, Volition is developing simple, easy to use, cost
effective blood tests to help diagnose and monitor a range of
life-altering diseases including some cancers and diseases
associated with NETosis such as sepsis and COVID-19. Early
diagnosis and monitoring have the potential to not only prolong the
life of patients but also improve their quality of life. The tests
are based on the science of Nucleosomics™, which is the practice of
identifying and measuring nucleosomes in the bloodstream or other
bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
For more information about Volition's Nu.Q® technology go to:
www.volition.com
The contents found at the Volition, the World Sepsis Day and the
World Health Organisation website addresses are not incorporated by
reference into this document and should not be considered part of
this document. The website addresses are included in this document
as inactive textual references only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's expectations related to the
timing and launch of product sales, and the potential uses,
benefits and effectiveness of its Nucleosomics™ technology
platform, including the Nu.Q® NETs test. Volition's
actual results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, results of studies testing the
efficacy of its tests, a failure by the marketplace to accept
Volition's, Nu.Q® NETs test or other products based on
its Nucleosomics™ platform; Volition's failure to secure adequate
intellectual property protection; Volition's failure to obtain
necessary regulatory clearances or approvals to distribute and
market future products; Volition will face fierce competition and
its intended products may become obsolete due to the highly
competitive nature of the diagnostics and disease monitoring
markets and their rapid technological change; downturns in domestic
and foreign economies; and other risks, including those identified
in Volition's most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as other documents that Volition
files with the Securities and Exchange Commission. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Forward-looking statements are based on current
expectations, estimates and projections about Volition's business
based, in part, on assumptions made by management. These statements
are not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original
content:https://www.prnewswire.com/news-releases/volition-hosts-key-opinion-leader-roundtable-on-sepsis-management-301925995.html
SOURCE VolitionRx Limited